In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery ...

The rate of cardiovascular death, nonfatal heart attack, or nonfatal stroke was 30% lower among patients receiving nurse-led ...

Panelists discuss how ruxolitinib cream demonstrated significant clinical efficacy in treating atopic dermatitis over a 12-month period, with claims analysis revealing improved disease control, ...

Factor XI Inhibitors are the alternative to DOACs, which are highly effective at preventing strokes. However, their bleeding risks often limit their use, especially in high-risk patients.

In an interview with Managed Healthcare Executive, Christian T. Ruff, M.D., M.P.H., director of general cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School, ...

John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's Diabetes Care Center, pointed to research that has shown a price of $150 ...

In this second part of his interview with Managed Healthcare Executive, John B. Buse, M.D., Ph.D., a professor at the University of North Carolina (UNC) School of Medicine and director of the UNC's ...